novel
coronaviru
infect
initi
found
end
attract
great
attent
far
number
infecti
case
increas
global
thousand
outbreak
defin
pandem
situat
still
specif
drug
avail
relev
report
point
novel
coronaviru
homolog
sar
difficulti
new
synthes
drug
appli
immedi
patient
convent
drug
new
use
becom
feasibl
solut
first
medic
experi
recov
patient
us
led
remdesivir
specif
drug
china
also
taken
immedi
action
put
remdesivir
clinic
trial
purpos
appli
clinic
therapeut
corona
viru
diseas
start
structur
immunogen
pathogenesi
coronaviru
infect
novel
coronaviru
analyz
pharmacolog
action
previou
trial
remdesivir
identifi
feasibl
conduct
experi
novel
coronaviru
offici
name
sever
acut
respiratori
syndrom
coronaviru
newlyemerg
human
infecti
coronaviru
sinc
decemb
spread
rapidli
china
short
period
time
march
confirm
case
death
also
outbreak
countri
korea
japan
itali
singapor
iran
total
case
confirm
due
newlyemerg
viru
research
taken
quick
action
isol
viru
perform
gene
sequenc
make
identifi
treatment
possibl
even
take
time
develop
new
drug
vaccin
well
explor
biotherapeut
thu
unlik
appli
patient
urgent
need
therefor
convent
drug
new
use
becom
viabl
solut
homolog
acut
respiratori
syndromeassoci
coronaviru
sarscov
also
broke
china
enzym
even
homolog
consequ
expect
find
drug
treatment
experi
sarscov
middl
east
respiratori
syndrom
merscov
drug
ribavirin
interferon
lopinavir
corticosteroid
use
patient
sar
mer
within
select
rang
convent
drug
new
use
clinic
treatment
covid
found
neuraminidas
inhibitor
oseltamivir
peramivir
zanamivir
ganciclovir
acyclovir
ribavirin
ineffectu
recommend
clinic
applic
set
sight
broadspectrum
antivir
drug
found
drug
unlist
remdesivir
demonstr
strength
trial
relat
merscov
ebola
viru
infect
unit
state
first
patient
shown
signific
improv
clinic
symptom
within
h
treatment
remdesivir
case
convinc
public
remdesivir
could
becom
new
specif
drug
articl
start
structur
immunogen
pathogenesi
infect
analyz
feasibl
conduct
trial
put
clinic
use
pharmacolog
characterist
success
case
remdesivir
differ
sarscov
merscov
becom
seventh
member
coronaviru
famili
infect
human
show
typic
beta
coronaviru
organ
untransl
region
utr
replic
enzym
code
region
gene
e
gene
gene
n
gene
utr
sever
unidentifi
nonstructur
open
read
frame
fig
replic
enzym
code
region
mainli
express
encod
two
larg
gene
encod
nonstructur
protein
highli
conserv
throughout
coronaviru
gene
gene
e
gene
n
gene
respect
encod
four
main
structur
protein
spike
membran
envelop
e
nucleocapsid
n
protein
protein
receptor
bind
site
viral
surfac
protein
shape
virion
promot
membran
curvatur
respons
transport
nutrient
across
cell
membran
e
protein
play
role
assembl
releas
viru
involv
viral
pathogenesi
n
protein
bind
viru
rna
genom
maintain
stabil
among
protein
play
key
role
viru
recogn
bind
host
cell
surfac
receptor
mediat
fusion
viru
envelop
cell
membran
analysi
whole
genom
sequenc
share
sequenc
similar
merscov
sequenc
similar
sarscov
indic
compat
sarscov
addit
perform
systemat
structur
simul
immunogen
scan
protein
coronavirus
well
calcul
immunogen
distanc
coronaviru
subtyp
conclud
immunogen
protein
closer
sarscov
known
sarscov
enter
target
cell
bind
protein
receptor
cell
surfac
trigger
cell
serin
proteas
view
amino
acid
similar
sarscov
specul
novel
coronaviru
may
similar
function
sarscov
preliminari
prove
bioinformat
predict
method
well
vitro
test
previou
studi
shown
key
amino
acid
protein
surfac
bind
angiotensinconvert
enzym
receptor
target
cell
chang
suspect
may
affect
affin
protein
receptor
turn
affect
spread
viru
among
public
howev
calcul
method
molecular
structur
simul
interact
protein
sarscov
receptor
perfectli
maintain
holist
manner
present
prove
bind
affin
extracellular
domain
protein
receptor
time
higher
sarscov
may
facilit
humantohuman
transmiss
respiratori
syndrom
caus
infect
gener
acut
resolv
diseas
common
symptom
onset
fever
dri
cough
fatigu
partli
nausea
diarrhea
gastrointestin
symptom
compar
sar
mer
milder
clinic
symptom
lower
fatal
also
fatal
sever
patient
may
develop
diffus
alveolar
injuri
progress
respiratori
failur
acut
respiratori
distress
syndrom
ard
similar
sarscov
receptor
bind
domain
rbd
protein
surfac
bind
receptor
cell
surfac
facilit
viru
enter
host
cell
viru
expos
rna
translat
rna
replicas
form
rna
replicasetranscriptas
complex
transcript
replic
complex
form
rna
neg
strand
translat
structur
protein
viru
later
structur
protein
rna
cytoplasm
assembl
new
viral
particl
releas
infect
cell
exocytosi
infect
cell
fig
infect
cell
produc
thousand
novel
viral
particl
spread
bronchi
eventu
reach
alveoli
extrapulmonari
organ
caus
pneumonia
target
organ
infect
howev
receptor
express
respiratori
organ
report
use
rnaseq
method
express
receptor
human
tissu
number
receptor
express
gastrointestin
tract
high
esophagu
small
intestin
colon
low
stomach
kidney
test
nearli
time
higher
lung
suggest
tissu
may
also
target
organ
invas
may
explain
patient
develop
system
injuri
clinic
besid
respiratori
system
injuri
furthermor
found
nucleic
acid
detect
posit
fece
patient
indic
may
live
viru
fece
digest
system
may
potenti
rout
addit
direct
damag
caus
viru
indirect
immun
injuri
caus
injur
tissu
also
attract
great
concern
may
relat
sever
fatal
diseas
previou
studi
shown
pulmonari
inflamm
extens
lung
injuri
patient
sar
associ
increas
proinflammatori
cytokin
serum
report
merscov
infect
induc
elev
proinflammatori
cytokin
concentr
serum
note
patient
also
high
level
serum
lead
activ
cell
respons
furthermor
concentr
gcsf
icu
patient
higher
nonicu
patient
indic
cytokin
storm
associ
diseas
sever
apart
infect
also
activ
secret
cytokin
cell
respons
suppress
inflamm
differ
sarscov
infect
research
need
investig
respons
infect
elucid
pathogenesi
current
pathogenesi
unclear
first
patholog
autopsi
patient
demonstr
lung
patient
review
diffus
alveolar
injuri
pulmonari
hyalin
membran
format
consist
ard
overal
patholog
manifest
lung
similar
sar
mer
flow
cytometri
signifi
number
lymphocyt
peripher
blood
greatli
reduc
state
overactiv
lymphocyt
highli
proinflammatori
effect
increas
lymphocyt
lymphocyt
high
concentr
cytotox
granul
perforin
posit
particl
lysin
posit
particl
lysin
perforin
posit
manifest
sever
immun
injuri
patient
may
close
link
overactiv
lymphocyt
character
increas
lymphocyt
high
cytotox
lymphocyt
presum
failur
develop
full
adapt
immun
respons
could
due
progress
pneumonia
rapid
allow
avail
establish
adapt
immun
respons
likewis
count
peripher
lymphocyt
substanti
reduc
lead
insuffici
immun
defens
furthermor
peripher
lymphocyt
overactiv
state
manifest
increas
high
cytotox
lymphocyt
account
certain
degre
immun
injuri
patient
activ
fail
establish
immun
respons
also
caus
tissu
injuri
mostli
manifest
sever
injuri
lung
patient
die
multipl
organ
failur
situat
acceler
deterior
shorten
cours
diseas
hamper
establish
fulli
adapt
immun
respons
immunopatholog
injuri
caus
activ
also
provid
us
idea
treat
exampl
probabl
appli
inhibitor
secukinwmab
direct
cell
activ
still
need
explor
also
vaccin
also
one
solut
make
lack
adapt
immun
respons
latest
studi
term
chang
viral
nucleic
acid
patient
similar
patient
influenza
differ
sar
viral
load
detect
symptomat
patient
also
asymptomat
patient
point
potenti
viru
transmiss
asymptomat
mildli
symptomat
patient
find
coher
report
evidenc
viru
transmiss
may
occur
earli
infecti
process
illustr
case
detect
isol
may
requir
differ
strategi
requir
control
sarscov
remdesivir
nucleosid
analogu
drug
fig
extens
antivir
activ
effect
treatment
lethal
ebola
nipah
viru
infect
nonhuman
primat
rnadepend
rna
polymeras
rdrp
inhibitor
inhibit
replic
multipl
coronavirus
respiratori
epitheli
cell
recent
studi
report
remdesivir
compet
natur
counterpart
atp
remdesivir
ad
grow
chain
posit
caus
immedi
stop
contrari
continu
extend
three
nucleotid
stop
strand
posit
fig
mous
sar
model
prevent
treatment
trial
remdesivir
achiev
satisfactori
result
administ
day
onset
diseas
lung
viru
titer
decreas
significantli
fig
invas
process
remdesivir
work
enter
target
cell
bind
protein
receptor
cell
surfac
remdeivir
nucleotid
analogu
act
rdrp
inhibitor
provid
scheme
block
rna
replic
remdesivir
ad
grow
chain
posit
caus
immedi
stop
contrari
continu
extend
three
nucleotid
stop
strand
posit
remdesivir
triphosph
remov
origin
structur
drug
deriv
drugbank
http
wwwdrugbankca
access
feb
improv
pulmonari
function
administ
day
onset
pulmonari
viru
titer
obvious
reduc
surviv
rate
mice
still
rel
low
studi
impli
pulmonari
injuri
reach
maximum
simpli
reduc
viru
titer
longer
suppress
strong
immun
respons
mice
also
show
administ
peak
viru
replic
significantli
improv
symptom
infect
mice
rhesu
monkey
model
infect
merscov
treat
remdesivir
h
infect
complet
prevent
symptom
caus
merscov
strongli
inhibit
viral
replic
respiratori
tract
prevent
format
pulmonari
lesion
administ
remdesivir
h
infect
provid
clear
clinic
benefit
reduc
clinic
symptom
lung
viru
replic
lung
lesion
pharmacokinet
experi
cynomolgu
monkey
show
firstpass
effect
oral
remdesivir
result
low
bioavail
drug
intramuscular
inject
mgkg
surviv
rate
compar
control
group
administ
intraven
dose
mgkg
remdesivir
rapidli
decompos
origin
drug
nucleosid
phosphat
rhesu
monkey
within
h
remdesivir
quickli
distribut
peripher
blood
mononuclear
cell
pbmc
soon
afterward
activ
nucleosid
triphosph
reach
peak
surviv
rate
pharmacokinet
studi
vivo
intraven
infus
remdesivir
solut
formul
singl
dose
mg
h
show
doselinear
pharmacokinet
intraven
infus
mg
remdesivir
solut
repeat
h
per
day
show
linear
pharmacokinet
period
day
intraven
inject
mg
remdesivir
solut
formul
h
pharmacokinet
profil
similar
lyophil
formul
intraven
infus
mg
drug
min
provid
similar
level
parent
drug
exposur
dose
h
tabl
intraven
infus
remdesivir
enter
cellular
metabol
form
activ
fig
frequenc
pbmc
exposur
higher
intraven
infus
remdesivir
mg
within
h
studi
pbmc
show
halflif
h
case
daili
administr
activ
substanc
drug
accumul
vivo
result
largescal
clinic
trial
first
dose
mg
administ
subsequ
dose
adjust
mg
ensur
proper
blood
concentr
vivo
intraven
infus
previous
phase
clinic
trial
good
safeti
pharmacokinet
properti
also
cytotox
hepatoren
toxic
seriou
advers
reaction
relat
meter
observ
climb
experi
subject
toler
studi
repeat
mg
intraven
daili
day
remdesivir
show
renal
injuri
multidos
studi
phase
ii
clinic
trial
conduct
ebola
virusinfect
patient
clinic
trial
antiebola
drug
fatal
rate
patient
experiment
group
use
remdesivir
efficaci
significantli
wors
two
monoclon
antibodi
fatal
rate
fatal
rate
fatal
rate
significantli
differ
averag
fatal
rate
ebola
viru
infect
result
phase
ii
clinic
trial
stop
nevertheless
consider
ebola
high
lethal
monoclon
antibodi
obviou
therapeut
effect
mere
patient
inject
remdesivir
assum
remdesivir
avail
small
sampl
size
enough
deni
effect
remdesivir
moreov
receptor
ebola
viru
wide
distribut
vivo
respiratori
tract
also
digest
tract
urinari
tract
blood
system
etc
caus
mortal
hemorrhag
fever
addit
ebola
viru
persist
eye
central
nervou
system
long
remdesivir
enter
bodi
quickli
distribut
testi
epididymi
eye
brain
rel
less
eye
brain
indic
wide
rang
spread
ebola
viru
high
lethal
tissu
make
remdesivir
control
ebola
ineffect
wuhan
viru
research
institut
conduct
vitro
experi
remdesivir
found
remdesivir
fastestact
power
antivir
agent
primari
cultur
human
airway
epitheli
cell
vitro
sarscov
ic
merscov
ic
dosedepend
effect
viru
inhibit
specul
relat
fact
remdesivir
triphosph
remov
conjectur
loss
function
exonucleas
may
involv
three
addit
nucleotid
ad
incorpor
remdesivir
extend
strand
vitro
anim
model
remdesivir
demonstr
activ
sar
mer
also
belong
coronavirus
theoret
provid
support
effect
treat
present
success
case
remdesivir
treat
new
england
journal
medicin
report
entir
cours
rehabilit
first
patient
unit
state
patient
visit
wuhan
neither
directli
expos
wuhan
seafood
market
direct
contact
diagnos
patient
return
washington
januari
januari
due
cough
fever
four
day
went
hospit
emerg
treatment
diagnos
condit
stabl
second
fifth
day
admiss
sixth
ninth
day
onset
even
fifth
day
admiss
blood
oxygen
satur
decreas
condit
continu
worsen
chest
radiograph
sixth
day
admiss
tenth
day
onset
show
typic
characterist
view
continu
aggrav
patient
clinic
symptom
physician
gave
charter
medic
compassion
use
remdesivir
even
day
admiss
began
give
intraven
patient
even
seventh
day
admiss
eleventh
day
onset
without
advers
reaction
vancomycin
discontinu
night
cefepim
discontinu
follow
day
eighth
day
admiss
twelfth
day
onset
patient
clinic
symptom
improv
oxygen
satur
increas
although
patient
still
hospit
januari
symptom
resolv
except
cough
occasion
run
nose
worth
note
data
articl
found
viral
load
patient
decreas
remdesivir
inject
tabl
describ
detail
origin
report
known
viral
infect
selflimit
patient
mild
moder
infecti
case
control
fever
time
thu
possibl
recoveri
relat
role
selfdefens
mechan
support
treatment
well
infer
tabl
drug
concentr
plasma
concentr
pharmacolog
activ
substanc
pbmc
healthi
peopl
improv
patient
condit
take
drug
definit
connect
remdesivir
whether
link
improv
symptom
drug
worth
consider
clinic
symptom
especi
respiratori
symptom
improv
significantli
within
h
bring
hope
treatment
patient
sever
specif
medic
avail
remdesivir
expect
specif
drug
howev
acut
infecti
diseas
reduc
number
viral
copi
bodi
key
point
also
efficaci
drug
focus
pharmacokinet
kinet
data
ongo
phase
iii
clinic
trial
outbreak
wuhan
constitut
epidem
threat
china
world
health
organ
announc
public
health
emerg
intern
concern
januari
outbreak
number
confirm
case
china
show
exponenti
growth
peopl
govern
countri
tri
best
fight
epidem
soar
combat
mood
nation
enthusiasm
fight
epidem
provid
trial
favor
environ
time
articl
china
new
drug
administr
law
came
effect
decemb
enabl
compassion
use
develop
adapt
china
two
clinic
trial
remdesivir
pass
stringent
ethic
review
project
februari
trial
offici
launch
experiment
drug
provid
gilead
scienc
free
china
professor
chen
wang
academician
chines
academi
engin
intern
renown
respiratori
expert
success
suggest
chines
govern
build
fang
cang
hospit
cure
thousand
mild
prepat
patient
due
larg
number
confirm
case
china
effect
drug
easi
collect
clinic
sampl
trial
theoret
howev
rigor
includ
sampl
hinder
recruit
public
attach
attent
prevent
treatment
fewer
patient
meet
stringent
inclus
criteria
result
slow
recruit
process
anoth
reason
plenti
drug
clinic
trial
speed
patient
leav
hospit
nevertheless
report
sever
patient
recruit
provid
favor
condit
trial
sever
group
result
least
rapidli
appli
clinic
treatment
sever
patient
near
futur
need
treatment
urgent
result
clinic
trial
prove
potenti
benefit
treatment
accord
china
compassion
use
remdesivir
immedi
use
patient
sever
ill
meanwhil
open
green
channel
special
circumst
speed
review
approv
process
drug
approv
center
undoubtedli
help
save
live
critic
patient
promot
develop
specif
drug
absenc
clinic
trial
result
still
difficult
put
remdesivir
larg
scale
clinic
use
polit
support
rapid
develop
clinic
trial
remdesivir
imper
drug
compound
fig
treat
felin
infecti
periton
fip
caus
coronaviru
infect
cat
test
cat
safeti
effect
treat
fip
proven
fda
approv
seen
structur
remdesivir
phosphoryl
ident
target
rdrp
fig
noteworthi
though
coronaviru
reproduc
gener
yield
resist
resist
viru
still
sensit
high
concentr
remdesivir
fit
resist
viru
reduc
level
wildtyp
merscov
avoid
resist
mutant
coronavirus
produc
resist
superviru
begin
develop
remdesivir
gilead
scienc
select
larg
number
nucleosid
prodrug
conduct
vitro
growth
inhibit
experi
ebolainfect
human
microvascular
endotheli
cell
laboratori
found
compound
show
inhibitori
activ
ec
compound
thereaft
basi
compound
examin
activ
toxic
compound
surround
compound
modifi
prodrug
optim
amino
acid
acyl
group
cynomolgu
monkey
perform
pharmacokinet
test
select
structur
fig
although
phase
ii
effect
competit
drug
clinic
trial
termin
remdesivir
show
good
safeti
pharmacokinet
phase
ii
clinic
trial
brought
remdesivir
stage
clinic
trial
whether
result
phase
iii
clinic
trial
make
comeback
stage
worthi
expect
phase
ii
clinic
trial
demonstr
human
toler
remdesivir
patient
phase
ii
clinic
trial
administ
remdesivir
report
seriou
advers
reaction
consid
relat
drug
sever
hypotens
thought
drugrel
still
confirm
drug
use
treat
fip
shown
high
degre
safeti
felin
trial
well
focal
inject
site
reaction
show
immedi
pain
vocal
occasion
growl
postur
chang
last
initi
reaction
reliev
owner
becam
adept
administ
inject
except
cat
slight
increas
urea
nitrogen
sdma
third
round
treatment
symptom
system
poison
observ
relev
research
signifi
larg
number
synthesi
structureact
analysi
toxic
greatli
reduc
synthes
remdesivir
safeti
remdesivir
human
specul
coronavirus
must
replic
nucleic
acid
gener
new
progeni
viru
enter
human
cell
known
singl
strand
rna
viru
rdrp
must
use
replic
nucleic
acid
remdesivir
nucleotid
analogu
act
rdrp
inhibitor
provid
scheme
block
rna
replic
relat
studi
found
play
role
final
stage
enter
cell
consist
expect
mode
action
wuhan
viru
research
institut
carri
vitro
inhibit
test
found
remdesivir
block
viru
infect
low
micromolar
concentr
vero
cell
infect
viru
cell
select
high
ec
cc
si
antiebola
infect
experi
cynomolgu
monkey
intraven
inject
mgkg
remdesivir
drug
exist
blood
long
time
inhibit
ebola
viru
percentag
wuhan
viru
research
institut
research
appli
remdesivir
vero
cell
ec
lower
monkey
model
draw
specul
could
also
play
role
infect
monkey
base
effect
previou
research
although
mani
unknown
limit
remdesivir
phase
iii
clinic
trial
fight
epidem
also
strateg
import
reserv
effect
antivir
drug
futur
strateg
reserv
antivir
drug
avoid
difficulti
medicin
unavail
outbreak
come
remdesivir
situat
polit
superior
well
previou
research
result
applic
effect
make
imper
carri
clinic
trial
focus
given
rna
viru
easi
mutat
rapid
start
clinic
trial
undoubtedli
right
choic
prevent
resist
mutat
due
blind
medic
cover
world
health
organ
directorgener
open
remark
media
brief
februari
two
clinic
trial
remdesivir
therapeut
priorit
r
blueprint
yc
cao
et
al
travel
medicin
infecti
diseas
xxx
xxxx
xxxx
expect
preliminari
result
three
week
februari
cast
vote
confid
gilead
scienc
experiment
antivir
drug
remdesivir
indic
remdesivir
great
potenti
may
best
candid
treatment
whatev
progress
clinic
trial
expect
clinic
trial
remdesivir
star
drug
would
bring
outstand
breakthrough
treatment
promisingli
viru
infect
futur
author
contribut
concept
review
yc
cao
qx
deng
review
literatur
draft
manuscript
sx
dai
critic
review
manuscript
author
contribut
revis
manuscript
author
report
conflict
